熱門資訊> 正文
Phathom表示FDA确认Voqueza独家经营权至2032年5月
2025-06-16 21:13
- Phathom Pharmaceuticals (NASDAQ:PHAT) said that the U.S. FDA has updated its "Orange Book" to reflect that Voquezna (vonoprazan) new chemical entity exclusivity is valid through May 3, 2032.
- The exclusivity applies to both the 10 mg and 20 mg tablets.
- Earlier this month, the FDA granted Phathom's Citizen Petition requesting the change.
More on Phathom Pharmaceuticals
- Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy
- Phathom: Share Price Surge On Patent News May Not Stop The Rot For Long
- Phathom Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation
- Phathom surges 125% after FDA grants petition on Voquezna exclusivity
- Phathom Pharmaceuticals surges 50% following large insider purchase
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
